Astrazeneca vs Merck &
Astrazeneca and Merck & are similar in size: $58.74bn and $65.01bn of revenue in their latest fiscal years. Astrazeneca grew faster (8.6% against 1.3%). Merck & kept more of each dollar of sales as profit: a net margin of 28.1% against 17.4%. Astrazeneca carries less debt relative to equity (60.9% against 93.8%).
| Latest fiscal year | AstrazenecaAZN, 2025 | Merck &MRK, 2025 |
|---|---|---|
| Revenue | $58.74bn | $65.01bn |
| Revenue growth | 8.6% | 1.3% |
| Net income | $10.22bn | $18.25bn |
| Operating margin | 23.4% | — |
| Net margin | 17.4% | 28.1% |
| Return on equity | 22.9% | 36.9% |
| Free cash flow | $11.77bn | $12.36bn |
| Cash | $5.71bn | $14.56bn |
| Total debt | $29.62bn | $49.34bn |
| Debt to equity | 60.9% | 93.8% |
| Dividend per share | — | $3.28 |
| Dividend yield | 1.7% | 2.3% |
| Share buybacks | $521m | $5.08bn |
| Employees | — | — |
| Market value | $286.25bn | $354.85bn |
| Price vs our value range | Within our value range | Above our value range |
| Moat score | — | 79 (Strong) |
| Insider trades, 12 months | 1 buys, 1 sales | 0 buys, 35 sales |